Indexé dans
  • Ouvrir la porte J
  • Genamics JournalSeek
  • Clés académiques
  • JournalTOCs
  • RechercheBible
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • Scimago
  • Répertoire des périodiques d'Ulrich
  • Bibliothèque des revues électroniques
  • RechercheRef
  • Université Hamdard
  • EBSCO AZ
  • OCLC - WorldCat
  • Catalogue en ligne SWB
  • Bibliothèque virtuelle de biologie (vifabio)
  • Publions
  • MIAR
  • Services d'indexation scientifique (SIS)
  • Pub européen
  • Google Scholar
Partager cette page
Dépliant de journal
Flyer image

Abstrait

Nanotechnology: Role Development Impact of Nanomedicine on Covid-19 Pandemic Management

Erum Alia

Extensive reports of pulmonary embolisms, ischaemic stroke and myocardial infarctions caused by coronavirus disease 2019 (COVID-19), as well as a significantly increased long-term risk of cardiovascular diseases in COVID-19 survivors, have highlighted severe deficiencies in our understanding of thromboinflammation and the need for new therapeutic options. Due to the complexity of the immunothrombosis pathophysiology, the efficacy of treatment with conventional anti-thrombotic medication is questioned. Thrombolytics do appear efficacious, but are hindered by severe bleeding risks, limiting their use. Nanomedicine can have profound impact in this context, protecting delicate (bio) pharmaceuticals from degradation en route and enabling delivery in a targeted and on demand manner. We provide an overview of the most promising nanocarrier systems and design strategies that may be adapted to develop nanomedicine for COVID-19-induced thromboinflammation, including dual-therapeutic approaches with antiviral and immunosuppressants. Resultant targeted and side-effect-free treatment may aid greatly in the fight against the ongoing COVID-19 pandemic.

Keywords

COVID-19; Nanotechnology; Nanomedicine; SARS-CoV-2

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié